BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer

Melinda M. Mortenson, Joseph M Galante, Oren Gilad, Michael G. Schlieman, Subbulakshmi Virudachalam, Hsing-Jien Kung, Richard J Bold

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

BCL-2 is the prototypic anti-apoptotic protein involved in the regulation of apoptosis. Overexpression of BCL-2 is common in pancreatic cancer and confers resistance to the apoptotic effect of chemo- and radiotherapy. Although these cellular effects of BCL-2 are traditionally related to pathways involving the mitochondrial membrane, we sought to investigate whether BCL-2 is involved in other signaling pathways regulating cell survival and focused on AKT. We examined the effect of overexpression of BCL-2 in the MIA-PaCa-2 human pancreatic cancer cell line on the function and subcellular location of AKT. We observed that the stable subclones of MIA-PaCa-2 overexpressing BCL-2 demonstrated increased activity of AKT as well as IKK (a downstream target of AKT), increasing the transcriptional activity of NF-κB. Using immunoprecipitation techniques, we observed co-immunoprecipitation of AKT and BCL-2. Immunocytochemistry demonstrated co-localization of BCL-2 and AKT, which was abrogated by treatment with HA14-1, a small molecule inhibitor of BH-3-mediated protein interaction by BCL-2. Furthermore, treatment with HA14-1 decreased phosphorylation of AKT and increased sensitivity to the apoptotic effect of the chemotherapeutic agent, paclitaxel. These results demonstrate an additional mechanism of regulation of cell survival mediated by BCL-2, namely through AKT activation, in the MIA-PaCa-2 pancreatic cancer cell line. Therefore, directed inhibition of BCL-2 may alter diverse pathways controlling cell survival and overcome the apoptotic resistance that is the hallmark of pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)1171-1179
Number of pages9
JournalJournal of Cellular Biochemistry
Volume102
Issue number5
DOIs
StatePublished - Dec 1 2007

Fingerprint

Activator Appliances
Pancreatic Neoplasms
Cells
Cell Survival
Immunoprecipitation
Cell Line
Apoptosis Regulatory Proteins
Mitochondrial Membranes
Paclitaxel
Phosphorylation
Chemotherapy
Radiotherapy
Immunohistochemistry
Apoptosis
Drug Therapy
Chemical activation
Membranes
Therapeutics
Molecules
Proteins

Keywords

  • AKT
  • BCL-2
  • Pancreatic cancer

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer. / Mortenson, Melinda M.; Galante, Joseph M; Gilad, Oren; Schlieman, Michael G.; Virudachalam, Subbulakshmi; Kung, Hsing-Jien; Bold, Richard J.

In: Journal of Cellular Biochemistry, Vol. 102, No. 5, 01.12.2007, p. 1171-1179.

Research output: Contribution to journalArticle

Mortenson, Melinda M. ; Galante, Joseph M ; Gilad, Oren ; Schlieman, Michael G. ; Virudachalam, Subbulakshmi ; Kung, Hsing-Jien ; Bold, Richard J. / BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer. In: Journal of Cellular Biochemistry. 2007 ; Vol. 102, No. 5. pp. 1171-1179.
@article{885bdababec64558bac077ff4a4fec52,
title = "BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer",
abstract = "BCL-2 is the prototypic anti-apoptotic protein involved in the regulation of apoptosis. Overexpression of BCL-2 is common in pancreatic cancer and confers resistance to the apoptotic effect of chemo- and radiotherapy. Although these cellular effects of BCL-2 are traditionally related to pathways involving the mitochondrial membrane, we sought to investigate whether BCL-2 is involved in other signaling pathways regulating cell survival and focused on AKT. We examined the effect of overexpression of BCL-2 in the MIA-PaCa-2 human pancreatic cancer cell line on the function and subcellular location of AKT. We observed that the stable subclones of MIA-PaCa-2 overexpressing BCL-2 demonstrated increased activity of AKT as well as IKK (a downstream target of AKT), increasing the transcriptional activity of NF-κB. Using immunoprecipitation techniques, we observed co-immunoprecipitation of AKT and BCL-2. Immunocytochemistry demonstrated co-localization of BCL-2 and AKT, which was abrogated by treatment with HA14-1, a small molecule inhibitor of BH-3-mediated protein interaction by BCL-2. Furthermore, treatment with HA14-1 decreased phosphorylation of AKT and increased sensitivity to the apoptotic effect of the chemotherapeutic agent, paclitaxel. These results demonstrate an additional mechanism of regulation of cell survival mediated by BCL-2, namely through AKT activation, in the MIA-PaCa-2 pancreatic cancer cell line. Therefore, directed inhibition of BCL-2 may alter diverse pathways controlling cell survival and overcome the apoptotic resistance that is the hallmark of pancreatic cancer.",
keywords = "AKT, BCL-2, Pancreatic cancer",
author = "Mortenson, {Melinda M.} and Galante, {Joseph M} and Oren Gilad and Schlieman, {Michael G.} and Subbulakshmi Virudachalam and Hsing-Jien Kung and Bold, {Richard J}",
year = "2007",
month = "12",
day = "1",
doi = "10.1002/jcb.21343",
language = "English (US)",
volume = "102",
pages = "1171--1179",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer

AU - Mortenson, Melinda M.

AU - Galante, Joseph M

AU - Gilad, Oren

AU - Schlieman, Michael G.

AU - Virudachalam, Subbulakshmi

AU - Kung, Hsing-Jien

AU - Bold, Richard J

PY - 2007/12/1

Y1 - 2007/12/1

N2 - BCL-2 is the prototypic anti-apoptotic protein involved in the regulation of apoptosis. Overexpression of BCL-2 is common in pancreatic cancer and confers resistance to the apoptotic effect of chemo- and radiotherapy. Although these cellular effects of BCL-2 are traditionally related to pathways involving the mitochondrial membrane, we sought to investigate whether BCL-2 is involved in other signaling pathways regulating cell survival and focused on AKT. We examined the effect of overexpression of BCL-2 in the MIA-PaCa-2 human pancreatic cancer cell line on the function and subcellular location of AKT. We observed that the stable subclones of MIA-PaCa-2 overexpressing BCL-2 demonstrated increased activity of AKT as well as IKK (a downstream target of AKT), increasing the transcriptional activity of NF-κB. Using immunoprecipitation techniques, we observed co-immunoprecipitation of AKT and BCL-2. Immunocytochemistry demonstrated co-localization of BCL-2 and AKT, which was abrogated by treatment with HA14-1, a small molecule inhibitor of BH-3-mediated protein interaction by BCL-2. Furthermore, treatment with HA14-1 decreased phosphorylation of AKT and increased sensitivity to the apoptotic effect of the chemotherapeutic agent, paclitaxel. These results demonstrate an additional mechanism of regulation of cell survival mediated by BCL-2, namely through AKT activation, in the MIA-PaCa-2 pancreatic cancer cell line. Therefore, directed inhibition of BCL-2 may alter diverse pathways controlling cell survival and overcome the apoptotic resistance that is the hallmark of pancreatic cancer.

AB - BCL-2 is the prototypic anti-apoptotic protein involved in the regulation of apoptosis. Overexpression of BCL-2 is common in pancreatic cancer and confers resistance to the apoptotic effect of chemo- and radiotherapy. Although these cellular effects of BCL-2 are traditionally related to pathways involving the mitochondrial membrane, we sought to investigate whether BCL-2 is involved in other signaling pathways regulating cell survival and focused on AKT. We examined the effect of overexpression of BCL-2 in the MIA-PaCa-2 human pancreatic cancer cell line on the function and subcellular location of AKT. We observed that the stable subclones of MIA-PaCa-2 overexpressing BCL-2 demonstrated increased activity of AKT as well as IKK (a downstream target of AKT), increasing the transcriptional activity of NF-κB. Using immunoprecipitation techniques, we observed co-immunoprecipitation of AKT and BCL-2. Immunocytochemistry demonstrated co-localization of BCL-2 and AKT, which was abrogated by treatment with HA14-1, a small molecule inhibitor of BH-3-mediated protein interaction by BCL-2. Furthermore, treatment with HA14-1 decreased phosphorylation of AKT and increased sensitivity to the apoptotic effect of the chemotherapeutic agent, paclitaxel. These results demonstrate an additional mechanism of regulation of cell survival mediated by BCL-2, namely through AKT activation, in the MIA-PaCa-2 pancreatic cancer cell line. Therefore, directed inhibition of BCL-2 may alter diverse pathways controlling cell survival and overcome the apoptotic resistance that is the hallmark of pancreatic cancer.

KW - AKT

KW - BCL-2

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=36849063240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849063240&partnerID=8YFLogxK

U2 - 10.1002/jcb.21343

DO - 10.1002/jcb.21343

M3 - Article

VL - 102

SP - 1171

EP - 1179

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 5

ER -